The Human Microbiome: An Overview of Microbial Mechanisms, Diagnostics, and Therapeutic Modulation in Cancer

Ismail Ibrahim Al-Janabi

doi:10.54133/ajms.v10i1.2474

Authors

Ismail Ibrahim Al-Janabi Retired Academic and Science Writer, Epsom, Surrey, United Kingdom https://orcid.org/0000-0003-2922-1790

DOI:

https://doi.org/10.54133/ajms.v10i1.2474

Keywords:

Human microbiome; microbiota; cancer; carcinogenesis

Abstract

The human microbiome consists of trillions of microbes (microorganisms) residing in various locations in the body, but primarily in the gut. It plays a vital role in health maintenance and influences several diseases, including cancer. Emerging evidence suggests that microbial dysbiosis, characterized by an imbalance in microbial numbers and diversity, may contribute to cancer development through several mechanisms, including the release of genotoxins, altered metabolism, immune system modulation, and chronic inflammation. This narrative review compiles existing insights into the interactions between the microbiome and cancer, with a particular emphasis on microbial mechanisms during carcinogenesis and the contributions of the microbiome to the diagnosis and treatment of cancer. We examine the potential use of prebiotics, probiotics, fecal microbiota transplants, and microbial therapies that may influence cancer and its response to treatment. Gaining a deeper understanding of the intricate relationship between microbial communities and cancer could lead to groundbreaking methods for cancer prevention and therapy.

Downloads

Download data is not yet available.

References

Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2024;385(6716):eadt2260. doi: 10.1126/science.adt2260. DOI: https://doi.org/10.1126/science.adt2260

Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, et al. Human gut microbiota in health and disease: Unveiling the relationship. Front Microbiol. 2022;13:999001. doi: 10.3389/fmicb.2022.999001. DOI: https://doi.org/10.3389/fmicb.2022.999001

Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. doi: 10.1371/journal.pbio.1002533. DOI: https://doi.org/10.1371/journal.pbio.1002533

Iebba V, Totino V, Gagliardi A, Santangelo F, Cacciotti F, Trancassini M, et al. Eubiosis and dysbiosis: the two sides of the microbiota. New Microbiol. 2016;39(1):1-12. PMID: 26922981.

Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368(6494):973-980. doi: 10.1126/science.aay9189. DOI: https://doi.org/10.1126/science.aay9189

Dion MB, Oechslin F, Moineau S. Phage diversity, genomics and phylogeny. Nat Rev Microbiol. 2020;18(3):125-138. doi: 10.1038/s41579-019-0311-5. DOI: https://doi.org/10.1038/s41579-019-0311-5

Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859-904. doi: 10.1152/physrev.00045.2009. DOI: https://doi.org/10.1152/physrev.00045.2009

Rajagopala SV, Vashee S, Oldfield LM, Suzuki Y, Venter JC, Telenti A, et al. The human microbiome and cancer. Cancer Prev Res (Phila). 2017;10(4):226-234. doi: 10.1158/1940-6207.CAPR-16-0249. DOI: https://doi.org/10.1158/1940-6207.CAPR-16-0249

Cullin N, Azevedo Antunes C, Straussman R, Stein-Thoeringer CK, Elinav E. Microbiome and cancer. Cancer Cell. 2021;39(10):1317-1341. doi: 10.1016/j.ccell.2021.08.006. DOI: https://doi.org/10.1016/j.ccell.2021.08.006

IARC monographs on the evaluation of carcinogenic risks to humans 100B. Available at: https://publications.iarc.fr/Book-And-Report-Series/IarcMonographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Biological-Agents-2012.

Gregory AC, Zablocki O, Zayed AA, Howell A, Bolduc B, Sullivan MB. The gut virome database reveals age-dependent patterns of virome diversity in the human gut. Cell Host Microbe. 2020;28(5):724-740.e8. doi: 10.1016/j.chom.2020.08.003. DOI: https://doi.org/10.1016/j.chom.2020.08.003

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423-37. doi: 10.1038/nm.3394. DOI: https://doi.org/10.1038/nm.3394

Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135. doi: 10.1038/s41392-022-00974-4. DOI: https://doi.org/10.1038/s41392-022-00974-4

Zhou P, Hu Y, Wang X, Shen L, Liao X, Zhu Y, et al. Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy. Front Immunol. 2022;13:877939. doi: 10.3389/fimmu.2022.877939. DOI: https://doi.org/10.3389/fimmu.2022.877939

Ding T, Liu C, Li Z. The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications. Mol Cancer. 2025;24(1):18. doi: 10.1186/s12943-025-02227-8. DOI: https://doi.org/10.1186/s12943-025-02227-8

Feng M, Cheng X. Parasite-associated cancers (Blood flukes/Liver flukes). Adv Exp Med Biol. 2017;1018:193-205. doi: 10.1007/978-981-10-5765-6_12. DOI: https://doi.org/10.1007/978-981-10-5765-6_12

Chen Z, Guan D, Wang Z, Li X, Dong S, Huang J, et al. Microbiota in cancer: molecular mechanisms and therapeutic interventions. MedComm (2020). 2023;4(6):e417. doi: 10.1002/mco2.417. DOI: https://doi.org/10.1002/mco2.417

Barrett M, Hand CK, Shanahan F, Murphy T, O'Toole PW. Mutagenesis by microbe: The role of the microbiota in shaping the cancer genome. Trends Cancer. 2020;6(4):277-287. doi: 10.1016/j.trecan.2020.01.019. DOI: https://doi.org/10.1016/j.trecan.2020.01.019

Wroblewski LE, Peek RM. Helicobacter pylori in gastric carcinogenesis: mechanisms. Gastroenterol Clin North Am. 2013;42(2):285-298. doi: 10.1016/j.gtc.2013.01.006. DOI: https://doi.org/10.1016/j.gtc.2013.01.006

Dzutsev A, Badger JH, Perez-Chanona E, Roy S, Salcedo R, Smith CK, et al. Microbes and cancer. Annu Rev Immunol. 2017;35:199-228. doi: 10.1146/annurev-immunol-051116-052133. DOI: https://doi.org/10.1146/annurev-immunol-051116-052133

Machado AM, Figueiredo C, Touati E, Máximo V, Sousa S, Michel V, et al. Helicobacter pylori infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells. Clin Cancer Res. 2009;15(9):2995-3002. doi: 10.1158/1078-0432.CCR-08-2686. DOI: https://doi.org/10.1158/1078-0432.CCR-08-2686

Mousa WK. The microbiome-product colibactin hits unique cellular targets mediating host-microbe interaction. Front Pharmacol. 2022;13:958012. doi: 10.3389/fphar.2022.958012. DOI: https://doi.org/10.3389/fphar.2022.958012

Kim JJ, Tao H, Carloni E, Leung WK, Graham DY, Sepulveda AR. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology. 2002;123(2):542-553. doi: 10.1053/gast.2002.34751. DOI: https://doi.org/10.1053/gast.2002.34751

Hsueh CY, Lau HC, Huang Q, Gong H, Sun J, Cao P, et al. Fusobacterium nucleatum impairs DNA mismatch repair and stability in patients with squamous cell carcinoma of the head and neck. Cancer. 2022;128(17):3170-3184. doi: 10.1002/cncr.34338. DOI: https://doi.org/10.1002/cncr.34338

Lu R, Wu S, Zhang YG, Xia Y, Liu X, Zheng Y, et al. Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway. Oncogenesis. 2014;3(6):e105. doi: 10.1038/oncsis.2014.20. DOI: https://doi.org/10.1038/oncsis.2014.20

Del Bel Belluz L, Guidi R, Pateras IS, Levi L, Mihaljevic B, Rouf SF, et al. The typhoid toxin promotes host survival and the establishment of a persistent asymptomatic infection. PLoS Pathog. 2016;12(4):e1005528. doi: 10.1371/journal.ppat.1005528. DOI: https://doi.org/10.1371/journal.ppat.1005528

Scanu T, Spaapen RM, Bakker JM, Pratap CB, Wu LE, Hofland I, et al. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. Cell Host Microbe. 2015;17(6):763-774. doi: 10.1016/j.chom.2015.05.002. DOI: https://doi.org/10.1016/j.chom.2015.05.002

Mu W, Jia Y, Chen X, Li H, Wang Z, Cheng B. Intracellular Porphyromonas gingivalis promotes the proliferation of colorectal cancer cells via the MAPK/ERK signaling pathway. Front Cell Infect Microbiol. 2020;10:584798. doi: 10.3389/fcimb.2020.584798. DOI: https://doi.org/10.3389/fcimb.2020.584798

Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013;496(7444):238-2342. doi: 10.1038/nature11986. DOI: https://doi.org/10.1038/nature11986

Benítez-Páez A, Gómez Del Pulgar EM, Sanz Y. The glycolytic versatility of Bacteroides uniformis CECT 7771 and its genome response to oligo and polysaccharides. Front Cell Infect Microbiol. 2017;7:383. doi: 10.3389/fcimb.2017.00383. DOI: https://doi.org/10.3389/fcimb.2017.00383

Donohoe DR, Holley D, Collins LB, Montgomery SA, Whitmore AC, Hillhouse A, et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov. 2014;4(12):1387-1397. doi: 10.1158/2159-8290.CD-14-0501. DOI: https://doi.org/10.1158/2159-8290.CD-14-0501

Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147-191. doi: 10.1152/physrev.00010.2008. DOI: https://doi.org/10.1152/physrev.00010.2008

Chen Z, Wang Z, Du Y, Shi H, Zhou W. The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate. Biochim Biophys Acta Rev Cancer. 2022;1877(6):188826. doi: 10.1016/j.bbcan.2022.188826. DOI: https://doi.org/10.1016/j.bbcan.2022.188826

Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492-506. doi: 10.1038/s41422-020-0332-7. DOI: https://doi.org/10.1038/s41422-020-0332-7

Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973-1980. doi: 10.1136/gutjnl-2015-310101. DOI: https://doi.org/10.1136/gutjnl-2015-310101

Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195-206. doi: 10.1016/j.chom.2013.07.012. DOI: https://doi.org/10.1016/j.chom.2013.07.012

Kim DJ, Park JH, Franchi L, Backert S, Núñez G. The Cag pathogenicity island and interaction between TLR2/NOD2 and NLRP3 regulate IL-1β production in Helicobacter pylori infected dendritic cells. Eur J Immunol. 2013;43(10):2650-2658. doi: 10.1002/eji.201243281. DOI: https://doi.org/10.1002/eji.201243281

Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491(7423):254-258. doi: 10.1038/nature11465. DOI: https://doi.org/10.1038/nature11465

Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91-119. doi: 10.1016/B978-0-12-800100-4.00003-9. DOI: https://doi.org/10.1016/B978-0-12-800100-4.00003-9

Xu M, Yamada M, Li M, Liu H, Chen SG, Han YW. FadA from Fusobacterium nucleatum utilizes both secreted and nonsecreted forms for functional oligomerization for attachment and invasion of host cells. J Biol Chem. 2007;282(34):25000-25009. doi: 10.1074/jbc.M611567200. DOI: https://doi.org/10.1074/jbc.M611567200

Haghi F, Goli E, Mirzaei B, Zeighami H. The association between fecal enterotoxigenic B. fragilis with colorectal cancer. BMC Cancer. 2019;19(1):879. doi: 10.1186/s12885-019-6115-1. DOI: https://doi.org/10.1186/s12885-019-6115-1

Ting NL, Lau HC, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut. 2022;71(7):1412-1425. doi: 10.1136/gutjnl-2021-326264. DOI: https://doi.org/10.1136/gutjnl-2021-326264

Bronckaers A, Balzarini J, Liekens S. The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy. Biochem Pharmacol. 2008;76(2):188-197. doi: 10.1016/j.bcp.2008.04.019. DOI: https://doi.org/10.1016/j.bcp.2008.04.019

Mahdy MS, Azmy AF, Dishisha T, Mohamed WR, Ahmed KA, Hassan A, et al. Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity. BMC Microbiol. 2023;23(1):53. doi: 10.1186/s12866-023-02791-3. DOI: https://doi.org/10.1186/s12866-023-02791-3

Uribe-Herranz M, Rafail S, Beghi S, Gil-de-Gómez L, Verginadis I, Bittinger K, et al. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J Clin Invest. 2020;130(1):466-479. doi: 10.1172/JCI124332. DOI: https://doi.org/10.1172/JCI124332

Kim YS, Kim J, Park SJ. High-throughput 16S rRNA gene sequencing reveals alterations of mouse intestinal microbiota after radiotherapy. Anaerobe. 2015;33:1-7. doi: 10.1016/j.anaerobe.2015.01.004. DOI: https://doi.org/10.1016/j.anaerobe.2015.01.004

Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR, Goodson JM. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med. 2005;3:27. doi: 10.1186/1479-5876-3-27. DOI: https://doi.org/10.1186/1479-5876-3-27

Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012;61(4):582-588. doi: 10.1136/gutjnl-2011-300784. DOI: https://doi.org/10.1136/gutjnl-2011-300784

Yan X, Yang M, Liu J, Gao R, Hu J, Li J, et al. Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res. 2015;5(10):3111-3122.

Liang JQ, Li T, Nakatsu G, Chen YX, Yau TO, Chu E, et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut. 2020;69(7):1248-1257. doi: 10.1136/gutjnl-2019-318532. DOI: https://doi.org/10.1136/gutjnl-2019-318532

Huang YF, Chen YJ, Fan TC, Chang NC, Chen YJ, Midha MK, et al. Analysis of microbial sequences in plasma cell-free DNA for early-onset breast cancer patients and healthy females. BMC Med Genomics. 2018;11(Suppl 1):16. doi: 10.1186/s12920-018-0329-y. DOI: https://doi.org/10.1186/s12920-018-0329-y

Chen H, Ma Y, Xu J, Wang W, Lu H, Quan C, et al. Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer. Cell Rep Med. 2024;5(4):101499. doi: 10.1016/j.xcrm.2024.101499. DOI: https://doi.org/10.1016/j.xcrm.2024.101499

Kandalai S, Li H, Zhang N, Peng H, Zheng Q. The human microbiome and cancer: a diagnostic and therapeutic perspective. Cancer Biol Ther. 2023;24(1):2240084. doi: 10.1080/15384047.2023.2240084. DOI: https://doi.org/10.1080/15384047.2023.2240084

Shiao SL, Kershaw KM, Limon JJ, You S, Yoon J, Ko EY, et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer Cell. 2021;39(9):1202-1213. doi: 10.1016/j.ccell.2021.07.002. DOI: https://doi.org/10.1016/j.ccell.2021.07.002

Oh B, Boyle F, Pavlakis N, Clarke S, Guminski A, Eade T, et al. Emerging evidence of the gut microbiome in chemotherapy: A clinical review. Front Oncol. 2021;11:706331. doi: 10.3389/fonc.2021.706331. DOI: https://doi.org/10.3389/fonc.2021.706331

Li S, Zhu S, Yu J. The role of gut microbiota and metabolites in cancer chemotherapy. J Adv Res. 2024;64:223-235. doi: 10.1016/j.jare.2023.11.027. DOI: https://doi.org/10.1016/j.jare.2023.11.027

Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967-970. doi: 10.1126/science.1240527. DOI: https://doi.org/10.1126/science.1240527

Roberti MP, Yonekura S, Duong CPM, Picard M, Ferrere G, Tidjani Alou M, et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat Med. 2020;26(6):919-931. doi: 10.1038/s41591-020-0882-8. DOI: https://doi.org/10.1038/s41591-020-0882-8

Tintelnot J, Xu Y, Lesker TR, Schönlein M, Konczalla L, Giannou AD, et al. Nature. 2023;615(7950):168-174. doi: 10.1038/s41586-023-05728-y. DOI: https://doi.org/10.1038/s41586-023-05728-y

Lehouritis P, Cummins J, Stanton M, Murphy CT, McCarthy FO, Reid G, et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015;5:14554. doi: 10.1038/srep14554. DOI: https://doi.org/10.1038/srep14554

Zhang M, Liu J, Xia Q. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target. Exp Hematol Oncol. 2023;12(1):84. doi: 10.1186/s40164-023-00442-x. DOI: https://doi.org/10.1186/s40164-023-00442-x

Elkrief A, Pidgeon R, Maleki Vareki S, Messaoudene M, Castagner B, Routy B. The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development. Nat Rev Drug Discov. 2025. doi: 10.1038/s41573-025-01211-7. DOI: https://doi.org/10.1038/s41573-025-01211-7

Kang X, Lau HC, Yu J. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy. Cell Rep Med. 2024;5(4):101478. doi: 10.1016/j.xcrm.2024.101478. DOI: https://doi.org/10.1016/j.xcrm.2024.101478

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079-1084. doi: 10.1126/science.aad1329. DOI: https://doi.org/10.1126/science.aad1329

Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8(4):403-416. doi: 10.1158/2159-8290.CD-17-1134. DOI: https://doi.org/10.1158/2159-8290.CD-17-1134

Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023;29(4):906-916. doi: 10.1038/s41591-023-02234-6. DOI: https://doi.org/10.1038/s41591-023-02234-6

Weniger M, Hank T, Qadan M, Ciprani D, Michelakos T, Niess H, et al. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Br J Surg. 2021;108(6):709-716. doi: 10.1002/bjs.12003. DOI: https://doi.org/10.1002/bjs.12003

Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, et al. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: A strategy to promote immunosurveillance against lung metastases. Cell Rep. 2018;24(13):3528-3538. doi: 10.1016/j.celrep.2018.08.090. DOI: https://doi.org/10.1016/j.celrep.2018.08.090

Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, et al. Antibiotics for cancer treatment: A double-edged sword. J Cancer. 2020;11(17):5135-5149. doi: 10.7150/jca.47470. DOI: https://doi.org/10.7150/jca.47470

Wang Z, Li L, Wang S, Wei J, Qu L, Pan L, et al. The role of the gut microbiota and probiotics associated with microbial metabolisms in cancer prevention and therapy. Front Pharmacol. 2022;13:1025860. doi: 10.3389/fphar.2022.1025860. DOI: https://doi.org/10.3389/fphar.2022.1025860

Lili Z, Junyan W, Hongfei Z, Baoqing Z, Bolin Z. Detoxification of cancerogenic compounds by lactic acid bacteria strains. Crit Rev Food Sci Nutr. 2018;58(16):2727-2742. doi: 10.1080/10408398.2017.1339665. DOI: https://doi.org/10.1080/10408398.2017.1339665

Rizvi ZA, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta SK, et al. High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. Sci Adv. 2021;7(37):eabg5016. doi: 10.1126/sciadv.abg5016. DOI: https://doi.org/10.1126/sciadv.abg5016

Bindels LB, Delzenne NM, Cani PD, Walter J. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol. 2015;12(5):303-310. doi: 10.1038/nrgastro.2015.47. DOI: https://doi.org/10.1038/nrgastro.2015.47

Verspreet J, Damen B, Broekaert WF, Verbeke K, Delcour JA, Courtin CM. A critical look at prebiotics within the dietary fiber concept. Annu Rev Food Sci Technol. 2016;7:167-190. doi: 10.1146/annurev-food-081315-032749. DOI: https://doi.org/10.1146/annurev-food-081315-032749

Li Y, Elmén L, Segota I, Xian Y, Tinoco R, Feng Y, et al. Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth. Cell Rep. 2020;30(6):1753-1766. doi: 10.1016/j.celrep.2020.01.035. DOI: https://doi.org/10.1016/j.celrep.2020.01.035

Nguyen NA, Jiang Y, McQuade JL. Eating away cancer: the potential of diet and the microbiome for shaping immunotherapy outcome. Front Immunol. 2024;15:1409414. doi: 10.3389/fimmu.2024.1409414. DOI: https://doi.org/10.3389/fimmu.2024.1409414

Kabwe M, Dashper S, Bachrach G, Tucci J. Bacteriophage manipulation of the microbiome associated with tumour microenvironments-can this improve cancer therapeutic response? FEMS Microbiol Rev. 2021;45(5):fuab017. doi: 10.1093/femsre/fuab017. DOI: https://doi.org/10.1093/femsre/fuab017

Guo C, An Q, Zhang LY, Wei XD, Xu J, Yu JY, et al. Intratumoral microbiota as cancer therapeutic target. Aging Med (Milton). 2024;7(5):636-644. doi: 10.1002/agm2.12359. DOI: https://doi.org/10.1002/agm2.12359

Greig SL. Talimogene Laherparepvec: First global approval. Drugs. 2016;76(1):147-154. doi: 10.1007/s40265-015-0522-7. DOI: https://doi.org/10.1007/s40265-015-0522-7

Al-Janabi II. Cancer Vaccines: Another aspect to immunotherapy. Al-Rafidain J Med Sci. 2024;7(1):34–45. doi: 10.54133/ajms.v7i1.1057. DOI: https://doi.org/10.54133/ajms.v7i1.1057

Wu X, Zhang T, Chen X, Ji G, Zhang F. Microbiota transplantation: Targeting cancer treatment. Cancer Lett. 2019;452:144-151. doi: 10.1016/j.canlet.2019.03.010. DOI: https://doi.org/10.1016/j.canlet.2019.03.010

Yang Y, An Y, Dong Y, Chu Q, Wei J, Wang B, et al. Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy. EBioMedicine. 2024;100:104967. doi: 10.1016/j.ebiom.2024.104967. DOI: https://doi.org/10.1016/j.ebiom.2024.104967

Kucerova P, Cervinkova M. Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment. Anticancer Drugs. 2016;27(4):269-277. doi: 10.1097/CAD.0000000000000337. DOI: https://doi.org/10.1097/CAD.0000000000000337

Mills H, Acquah R, Tang N, Cheung L, Klenk S, Glassen R, et al. The Use of Bacteria in Cancer Treatment: A Review from the Perspective of Cellular Microbiology. Emerg Med Int. 2022 Aug 8;2022:8127137. doi: 10.1155/2022/8127137. DOI: https://doi.org/10.1155/2022/8127137

Chumchalová J, Smarda J. Human tumor cells are selectively inhibited by colicins. Folia Microbiol (Praha). 2003;48(1):111-115. doi: 10.1007/BF02931286. DOI: https://doi.org/10.1007/BF02931286

Villarante KI, Elegado FB, Iwatani S, Zendo T, Sonomoto K, de Guzman EE. Purification, characterization and in vitro cytotoxicity of the bacteriocin from Pediococcus acidilactici K2a2-3 against human colon adenocarcinoma (HT29) and human cervical carcinoma (HeLa) cells. World J Microbiol Biotechnol. 2011;27,975-980. doi: 10.1007/s11274-010-0541-1. DOI: https://doi.org/10.1007/s11274-010-0541-1

Aganja RP, Sivasankar C, Senevirathne A, Lee JH. Salmonella as a promising curative tool against cancer. Pharmaceutics. 2022;14(10):2100. doi: 10.3390/pharmaceutics14102100. DOI: https://doi.org/10.3390/pharmaceutics14102100